Medicines that either have a questionable level of added benefit or are innovative products for which a substantial benefit is expected but where evidence uncertainties remain are the most likely to be met with requests for post-market data collection, according to a new study from the health technology assessment (HTA) department at France’s HAS (Haute Autorité de Santé).
France Reveals The Drugs That Are Most Likely To Require Post-Market RWE Studies
A study from the health technology assessment department of France’s national health agency, HAS, has identified which pharmaceutical products are most likely to receive a request for post-market studies. The agency hopes this information will aid in companies’ forward planning.
